ESR1 and breast cancer: Similarly, distant recurrence-free interval (DRFI) of patients treated with TAM was significantly improved compared with those with no TAM in ER + /HER2− postmenopausal breast cancer when TIL-low group (< 10%) was considered (HR 0.49, 95% CI 0.31–0.78, p = 0.002).